Cryo-Cell International, Inc. (CCEL): History, Ownership, Mission, How It Works & Makes Money

Ever wondered about the company that pioneered cord blood banking? Cryo-Cell International Inc. (CCEL), the world's first private cord blood bank founded in 1989, stands as a foundational entity in cellular processing and cryogenic storage. With $32.0 million in consolidated revenues for fiscal year 2024 and a distinctive position in the stem cell banking market, what makes Cryo-Cell a leader in its field, and how does it plan to expand its reach in regenerative medicine? Keep reading to discover its history, ownership structure, operational model, and revenue generation strategies.

Cryo-Cell International, Inc. (CCEL) History

Cryo-Cell International, Inc. Founding Timeline

Year established

The company was established in 1989.

Original location

The company was founded in Clearwater, Florida.

Founding team members

The founder and first medical director was Dr. David G. Harris. In 1992, the company hired Daniel J. Jurin as the Chief Executive Officer.

Initial capital/funding

Information regarding the initial capital or funding for the company is not readily available.

Cryo-Cell International, Inc. Evolution Milestones

Cryo-Cell International, Inc. Transformative Moments

• Offering Cord Tissue Cryopreservation (2007): Cryo-Cell International became the first private cord blood bank to offer cord tissue cryopreservation, which allowed them to store mesenchymal stem cells (MSCs) found in cord tissue, expanding the therapeutic potential beyond cord blood-derived hematopoietic stem cells.
• Expansion into Menstrual Blood Stem Cell Storage (2017): By expanding the PRESERVE program to include the collection and storage of menstrual blood stem cells, the company tapped into the regenerative medicine market for women's health.
• Strategic Partnership with Generate Life Sciences (2023): This partnership allowed the company to leverage Generate Life Sciences' extensive network and resources, enhancing market penetration and service capabilities.

For more insights into the company's financial performance, you can read this article: Breaking Down Cryo-Cell International, Inc. (CCEL) Financial Health: Key Insights for Investors

Cryo-Cell International, Inc. (CCEL) Ownership Structure

Understanding the ownership structure of a company provides valuable insights into its control and governance. As of April 2025, the ownership of Cryo-Cell International Inc. is distributed among various shareholders, including institutional investors, retail investors, and potentially company insiders.

Cryo-Cell International, Inc.'s Current Status

Cryo-Cell International, Inc. is a public company, trading on the OTC market under the ticker symbol CCEL. This means that its shares are available for purchase by the general public.

Cryo-Cell International, Inc.'s Ownership Breakdown

The following table provides an overview of the ownership breakdown of Cryo-Cell International, Inc., offering a snapshot of the distribution of shares among different types of shareholders.

Cryo-Cell International, Inc.'s Leadership

The leadership team plays a crucial role in guiding the strategic direction and operational execution of Cryo-Cell International, Inc. As of April 2025, the key members of the leadership team include:

• David Portnoy: Chairman of the Board
• Jaime G. Suchlicki: Chief Executive Officer
• Savita Dhanvantari: Chief Operating Officer, Laboratory Director

These individuals hold significant responsibility for the company's performance and governance. For more insights into the company's values, review Mission Statement, Vision, & Core Values of Cryo-Cell International, Inc. (CCEL).

Cryo-Cell International, Inc. (CCEL) Mission and Values

Cryo-Cell International's mission is centered around providing clients with advanced cellular cryopreservation services, emphasizing quality and innovation. The company values advancements in stem cell technology and client satisfaction.

Cryo-Cell International, Inc.'s Core Purpose

Official mission statement

Cryo-Cell International, Inc. does not have a formal, publicly stated mission statement available in its 2024 fiscal year filings or recent corporate communications. However, information from their website and other sources indicates their mission is focused on:

• Preserving family health by cryopreserving stem cells.
• Advancing regenerative medicine through stem cell storage and research.
• Providing high-quality and reliable cryopreservation services.

Essentially, the company aims to be a leader in stem cell cryopreservation, ensuring that clients have access to innovative and reliable storage solutions for potential future medical needs. For more insights into the company's financial stability and growth, check out Breaking Down Cryo-Cell International, Inc. (CCEL) Financial Health: Key Insights for Investors.

Vision statement

Similar to the mission statement, Cryo-Cell International, Inc. does not have a single, explicitly defined vision statement. Instead, its vision can be inferred from its strategic goals and long-term objectives, which include:

• Expanding its global reach in stem cell cryopreservation services.
• Remaining at the forefront of stem cell technology and research.
• Enhancing customer experience through superior service and innovative offerings.

The company envisions a future where stem cell therapies are more accessible, and it positions itself as a key facilitator in making this vision a reality through its cryopreservation services.

Company slogan/tagline

While specific slogans may vary over time, Cryo-Cell International, Inc. has used taglines that reflect its core services and value proposition. These include:

• 'Your Baby's Future. Preserved.' - Highlights the focus on newborn stem cell storage.
• 'The Future of Stem Cell Banking.' - Emphasizes innovation and leadership in the industry.

These taglines underscore the company's commitment to safeguarding future health through advanced stem cell cryopreservation technology.

Cryo-Cell International, Inc. (CCEL) How It Works

Cryo-Cell International, Inc. primarily operates by providing cryogenic preservation of umbilical cord blood and umbilical cord tissue. This service allows parents to store their newborn's stem cells for potential future medical use.

Cryo-Cell International's Product/Service Portfolio

Cryo-Cell International's Operational Framework

Cryo-Cell International's operational framework is built around the collection, processing, and storage of stem cells. Here's a breakdown:

• Collection Kits: Cryo-Cell provides collection kits to expectant parents. These kits are used at the time of birth to collect umbilical cord blood and tissue.
• Transportation: The collected samples are transported to Cryo-Cell's processing facility.
• Processing: Upon arrival, the cord blood and tissue are processed to isolate and prepare the stem cells for cryopreservation.
• Cryopreservation: The stem cells are then cryogenically preserved in specialized storage tanks, maintained at extremely low temperatures to ensure their viability for future use.
• Storage: Cryo-Cell stores the stem cells for the duration of the client's contract, which can span several years.
• Client Services: They offer ongoing client support, including information on stem cell therapies and assistance with retrieving the stored stem cells if needed for medical treatment.

For more insights into the company's financial stability, check out: Breaking Down Cryo-Cell International, Inc. (CCEL) Financial Health: Key Insights for Investors

Cryo-Cell International's Strategic Advantages

Cryo-Cell International's success and competitive positioning are supported by several strategic advantages:

• Established Reputation: With over 35 years in the industry, Cryo-Cell has built a strong reputation and brand recognition among expectant parents.
• Proprietary Processing Methods: Cryo-Cell employs proprietary methods for stem cell processing and cryopreservation, potentially offering superior cell viability and recovery rates.
• Focus on Innovation: The introduction of C'elle demonstrates a commitment to innovation and expanding the applications of stem cell banking.
• Accreditations and Certifications: Holding key industry accreditations and certifications ensures high standards of quality and regulatory compliance, enhancing customer trust.

Cryo-Cell International, Inc. (CCEL) How It Makes Money

Cryo-Cell International, Inc. primarily generates revenue through the cryopreservation of umbilical cord blood and umbilical cord tissue, along with related services. These services cater to parents who wish to store their newborn's stem cells for potential future medical use.

Cryo-Cell International, Inc.'s Revenue Breakdown

As the latest complete fiscal year is 2024, the revenue streams and percentages are based on the 2024 data.

Cryo-Cell International, Inc.'s Business Economics

• Pricing Strategy: The company employs a premium pricing strategy, reflecting the specialized nature of its services and the long-term storage it provides. Prices vary based on the storage duration and any additional services included in the package.
• Economic Fundamentals: Demand is driven by parental awareness of the potential benefits of stem cell therapies and increasing healthcare expenditure. The business model benefits from recurring revenue through annual storage fees.
• Market Position: As one of the established players in the cord blood banking industry, the company benefits from brand recognition and customer trust.

Cryo-Cell International, Inc.'s Financial Performance

• Revenue Growth: The company has demonstrated steady revenue growth, driven by increased awareness of cord blood and cord tissue banking.
• Profitability: Profitability is maintained through efficient operational management and a focus on high-margin services.
• Key Metrics:
  • Gross Profit Margin: Consistently above 60%, reflecting strong pricing power and efficient cost management.
  • Operating Income: Demonstrates a healthy operating income, indicating effective management of operating expenses.

To gain more insights into the company's values and long-term goals, you might find this resource helpful: Mission Statement, Vision, & Core Values of Cryo-Cell International, Inc. (CCEL).

Cryo-Cell International, Inc. (CCEL) Market Position & Future Outlook

As of April 2025, Cryo-Cell International, Inc. is strategically positioned to leverage its established brand and expertise in the cryopreservation of stem cells, particularly from umbilical cord blood. The company aims to solidify its market presence and explore growth opportunities within the expanding regenerative medicine sector. For detailed insights into the company's financial standing, see: Breaking Down Cryo-Cell International, Inc. (CCEL) Financial Health: Key Insights for Investors

Competitive Landscape

Opportunities & Challenges

Industry Position

• Cryo-Cell International holds a significant position in the private cord blood banking industry, focusing on the collection, processing, and storage of umbilical cord blood stem cells.
• The company differentiates itself through technological advancements and customer-focused services.
• It faces competition from larger players and must continue to innovate and adapt to market changes to maintain its standing.